Press releases

WINNIPEG, Manitoba (June 17, 2004) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms, is pleased to announce the appointment of Dr. Dennis Cvitkovitch to its Scientific Advisory Board. Dr. Cvitkovitch, who brings considerable experience in understanding harmful bacteria and their role in bacterial biofilms, joins Dr. Tony Romeo, of Emory University, and Dr. George Zhanel, of the University of Manitoba, in advising Kane Biotech on its scientific and product development strategy.

Biofilms cost industry, cities and hospitals in excess of $500 Billion each year. Researchers have only recently begun to appreciate the significance of biofilms and the ramifications of their existence. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack.

"Dr. Cvitkovitch's appointment is a significant addition to Kane Biotech's scientific resources," said Mr. Marcus Enns, President of Kane Biotech. "It is widely recognized that new types of therapeutics and products will be required to combat the problems caused by biofilms and the key to developing these products is an in depth understanding of the science behind biofilm formation. Dr. Cvitkovitch enhances our understanding and complements our expertise in the biofilm area."

When in a biofilm, bacteria become highly resistant to antibiotics and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay. Biofilms are estimated to be responsible for 65% of all human infections.

"The Company is excited to have access to Dr. Cvitkovitch's substantial expertise and insight into the biofilm problem and its major effect on human health," added Mr. Enns. "Building relationships with talented researchers and leading biofilm and infectious disease experts is a key component of Kane Biotech's strategy to expand on the Company's technology and to commercialize anti-biofilm products."

About Dr. Dennis Cvitkovitch
Dr. Cvitkovitch is Professor, Faculty of Dentistry, University of Toronto, where he has been on the faculty since 1998. His research focus uses a variety of biochemical, molecular biological and in silico technologies to understand the mechanisms of cell-to-cell signaling and its role in biofilm formation and genetic exchange. Dr. Cvitkovitch has a Ph.D. in Oral Biology from the University of Manitoba and currently holds a prestigious Canada Research Chair. In addition, he holds grants from the National Institutes of Health in the United States, Canadian Institutes of Health Research, National Science and Engineering Research Council and the Canadian Foundation for Innovation.

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. The Company's technology focuses on the genetic mechanisms of biofilm formation, and builds upon the discovery of over 60 novel anti-biofilm targets. Biofilms are microbial populations in a self-produced matrix able to withstand high temperatures, host immune responses and antibiotics.

For more information, please contact:

Marcus Enns
President
Kane Biotech Inc.
204-487-2328 phone
204-488-9823 fax
info@kanebiotech.com
www.kanebiotech.com

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. This release is not to be construed as an offer to sell, or a solicitation for an offer to buy or trade securities